Article ID Journal Published Year Pages File Type
9601022 Clinical Oncology 2005 5 Pages PDF
Abstract
The combination of gemcitabine and moderate-dose radiation therapy is feasible, and offers low toxicity and excellent response rates in patients with localised NSCLC not suitable for high-dose therapy.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Oncology
Preview
A Phase I Study of Moderate-dose Radiation Therapy and Weekly Gemcitabine in Patients with Locally Advanced Non-small Cell Lung Cancer Not Suitable for Radical Chemoradiation Therapy
Authors
, , , , , ,